North America dominates the Veterinary Diagnostic Laboratory market with a 42% share, driven by the highest pet insurance penetration (35%), USDA’s NAHLN funding, and entrenched reference-lab chains leveraging AI-driven assays. Europe (28%) follows, propelled by the EU Animal Health Law, €2.4bn Horizon-Europe vet-tech grants, and rising demand for antimicrobial-resistance surveillance. Asia Pacific is the fastest-growing region (19% share, 11% CAGR) as China’s five-year veterinary infrastructure plan, India’s NPSS dairy genomics push, and booming pet humanisation in Japan/Korea attract record diagnostics PE investments. Latin America (7%) benefits from Brazil’s MAPA accreditation mandates for export-oriented protein producers, expanding university–industry labs, and growing pet populations in urban centres. Middle East & Africa (4%) is scaling through Gulf sovereign wealth funding of state-of-the-art central labs, South African OIE-compliant hubs serving the continent, and rising zoonotic-disease awareness amid intensified livestock production. Overall Veterinary Diagnostic Laboratory market growth is underpinned by policy alignment, demographic tailwinds, and rapid ecosystem maturation across all regions, with the regional forecast indicating continued polarisation toward high-value diagnostics and point-of-care decentralisation.
